Higher Recorded Tirzepatide Doses Track With Earlier Treatment Discontinuation
A Polish study links higher first recorded tirzepatide doses to earlier discontinuation, but cannot establish whether cost or side effects explain why.
Summary
Tirzepatide can treat obesity and type 2 diabetes, but continued use matters for maintaining its benefits. Researchers examined prescription records for 3,030 adults in Poland, where patients largely fund obesity medications themselves. Higher first recorded doses were associated with earlier loss of observed treatment compared with 2.5 mg. Among 385 patients with at least 180 days of observed treatment, prescriptions covered a median of 86% of days, and 68% met the study's adherence threshold. Only 25.8% of eligible patients with lower recorded doses reached at least 10 mg. The findings suggest clinicians should discuss costs, expectations, and tolerability, but these factors were not measured. Prescription records cannot confirm actual medication use, and the first recorded dose may not be the true starting dose. This summary is based on the abstract only.
Detailed Summary
Tirzepatide can help treat obesity and type 2 diabetes, but benefits depend on whether patients continue treatment. A Polish study examined prescription patterns in a setting where patients pay substantial costs themselves. It highlights a practical challenge for metabolic health: access to an effective medication does not necessarily translate into sustained use over time.
Researchers retrospectively analyzed electronic health records from a large private healthcare provider across Poland. They included 3,030 adults whose first recorded tirzepatide prescription occurred between November 2023 and February 2025. Women represented 69% of participants; 83.3% had obesity and 20% had type 2 diabetes. The study assessed observed treatment discontinuation, prescription coverage, and escalation from lower doses to at least 10 mg.
Compared with a first recorded dose of 2.5 mg, doses of 15 mg and 10 mg were associated with 44% and 24% higher discontinuation hazards, respectively. Among 385 patients who remained on observed treatment for at least 180 days, median prescription coverage was 86%, and 68% met the study's adherence threshold. Common coexisting conditions did not independently predict persistence.
Only 565 of 2,194 eligible patients with lower recorded doses reached at least 10 mg, or 25.8%. These findings support discussing treatment costs, expectations, and tolerability before prescribing and throughout follow-up. However, reaching a higher dose is not automatically better for every patient, and this study does not establish that changing the starting dose would improve persistence or clinical outcomes.
This summary is based on the abstract only. Prescription records cannot confirm actual injections or distinguish true discontinuation from care outside the provider. First recorded doses may not represent actual treatment initiation. Affordability, tolerability, and patient expectations were not measured directly, so their role remains speculative. The abstract provides no weight changes, glucose outcomes, or evidence of longer life or improved long-term health from persistence.
Key Findings
- First recorded doses of 15 mg and 10 mg were associated with 44% and 24% higher discontinuation hazards than 2.5 mg.
- Among 385 patients persistent for at least 180 days, median prescription coverage was 86%; 68% met the adherence threshold.
- Only 25.8% of eligible patients with lower recorded doses escalated to at least 10 mg.
- Traditional coexisting conditions did not independently predict treatment persistence.
- Discuss affordability, tolerability, and expectations, but recognize that this study did not measure their effects.
Methodology
This retrospective observational cohort used nationwide electronic health records from one large Polish private healthcare provider, including 3,030 adults with first recorded prescriptions from November 2023 through February 2025. Multivariable Cox regression assessed discontinuation predictors; adherence used proportion of days covered, and successful titration meant escalation from 2.5 or 5 mg to at least 10 mg. Discontinuation hazard ratios were 1.44 for 15 mg (95% CI 1.26–1.64) and 1.24 for 10 mg (95% CI 1.12–1.39), compared with 2.5 mg.
Study Limitations
This summary is based on the abstract only, and the retrospective observational design cannot establish causation. Prescription records may miss treatment obtained elsewhere, do not verify injections, and may not identify the actual starting dose; adherence estimates apply only to the subgroup persistent for at least 180 days. Costs, tolerability, and expectations were not directly measured, and the abstract reports no weight, glucose, or long-term health outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: